

# Anja Haltner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7099372/publications.pdf>

Version: 2024-02-01

7  
papers

62  
citations

1684188

5  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

49  
citing authors

| # | ARTICLE   | IF  | CITATIONS |
|---|---|-----|-----------|
| 1 | Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 109-120.  | 1.4 | 6         |
| 2 | Meta-analysis of ciltacabtagene autoleucl versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2022, 38, 1759-1767.  | 1.9 | 5         |
| 3 | Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 457-467.   | 1.4 | 10        |
| 4 | Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucl in CARTITUDE-1 versus idcabtagene vicleucl in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2021, 37, 1779-1788. | 1.9 | 21        |
| 5 | Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. <i>Current Medical Research and Opinion</i> , 2021, 37, 1-12.  | 1.9 | 4         |
| 6 | The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2020, 36, 1145-1156.                | 1.9 | 5         |
| 7 | Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2020, 36, 1157-1166.   | 1.9 | 11        |